• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酒精使用障碍:病理生理学、影响及治疗的药理学选择

Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

作者信息

Wackernah Robin C, Minnick Matthew J, Clapp Peter

机构信息

Department of Pharmacy Practice, School of Pharmacy, Rueckert-Hartman College for Health Professions, Regis University, Denver, CO, USA.

Department of Pharmaceutical Sciences, School of Pharmacy, Rueckert-Hartman College for Health Professions, Regis University, Denver, CO, USA.

出版信息

Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014.

DOI:10.2147/SAR.S37907
PMID:24648792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3931699/
Abstract

Alcohol use disorders (AUD) continue to be a concerning health issue worldwide. Harmful alcohol use leads to 2.5 million deaths annually worldwide. Multiple options exist for the management of dependence on alcohol, not all of which are approved by drug-regulating agencies. Current practice in treating AUD does not reflect the diversity of pharmacologic options that have potential to provide benefit, and guidance for clinicians is limited. Few medications are approved for treatment of AUD, and these have exhibited small and/or inconsistent effects in broad patient populations with diverse drinking patterns. The need for continued research into the treatment of this disease is evident in order to provide patients with more specific and effective options. This review describes the neurobiological mechanisms of AUD that are amenable to treatment and drug therapies that target pathophysiological conditions of AUD to reduce drinking. In addition, current literature on pharmacologic (both approved and non-approved) treatment options for AUD offered in the United States and elsewhere are reviewed. The aim is to inform clinicians regarding the options for alcohol abuse treatment, keeping in mind that not all treatments are completely successful in reducing craving or heavy drinking or increasing abstinence.

摘要

酒精使用障碍(AUD)在全球范围内仍然是一个令人担忧的健康问题。有害饮酒每年在全球导致250万人死亡。对于酒精依赖的管理有多种选择,但并非所有这些选择都得到了药物监管机构的批准。目前治疗AUD的做法并未反映出具有潜在益处的药理学选择的多样性,并且针对临床医生的指导有限。很少有药物被批准用于治疗AUD,而且这些药物在具有不同饮酒模式的广泛患者群体中显示出微小和/或不一致的效果。为了给患者提供更具体、有效的选择,继续研究这种疾病的治疗方法的必要性显而易见。本综述描述了适合治疗的AUD神经生物学机制以及针对AUD病理生理状况以减少饮酒的药物疗法。此外,还综述了美国和其他地方提供的关于AUD的药理学(包括已批准和未批准的)治疗选择的当前文献。目的是让临床医生了解酒精滥用治疗的选择,同时要记住并非所有治疗在减少渴望或重度饮酒或增加戒酒方面都能完全成功。

相似文献

1
Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.酒精使用障碍:病理生理学、影响及治疗的药理学选择
Subst Abuse Rehabil. 2014 Jan 23;5:1-12. doi: 10.2147/SAR.S37907. eCollection 2014.
2
New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.澳大利亚新的酒精问题治疗指南:推荐意见概述。
Med J Aust. 2021 Oct 4;215 Suppl 7:S3-S32. doi: 10.5694/mja2.51254.
3
Baclofen for alcohol use disorder.巴氯芬治疗酒精使用障碍。
Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD012557. doi: 10.1002/14651858.CD012557.pub3.
4
Rates of discontinuation and non-publication of trials for the pharmacologic treatment of alcohol use disorder.药物治疗酒精使用障碍试验的停药率和不发表率。
Subst Abus. 2022;43(1):906-912. doi: 10.1080/08897077.2021.2010261.
5
Targeting Epigenetic Mechanisms to Treat Alcohol Use Disorders (AUD).靶向表观遗传机制治疗酒精使用障碍(AUD)。
Curr Pharm Des. 2021 Oct 5;27(30):3252-3272. doi: 10.2174/1381612827666210203142539.
6
Alcohol craving and withdrawal at treatment entry prospectively predict alcohol use outcomes during outpatient treatment.治疗开始时的酒精渴求与戒断症状前瞻性地预测了门诊治疗期间的酒精使用结局。
Drug Alcohol Depend. 2022 Feb 1;231:109253. doi: 10.1016/j.drugalcdep.2021.109253. Epub 2021 Dec 31.
7
Overview of Alcohol Use Disorder.酒精使用障碍概述。
Am J Psychiatry. 2023 Aug 1;180(8):565-572. doi: 10.1176/appi.ajp.20230488.
8
Desire thinking as a predictor of drinking status following treatment for alcohol use disorder: A prospective study.治疗酒精使用障碍后,以欲望思维预测饮酒状态:一项前瞻性研究。
Addict Behav. 2019 Aug;95:70-76. doi: 10.1016/j.addbeh.2019.03.004. Epub 2019 Mar 5.
9
Association of Prefrontal-Striatal Functional Pathology With Alcohol Abstinence Days at Treatment Initiation and Heavy Drinking After Treatment Initiation.前额叶-纹状体功能病理学与治疗开始时的酒精戒断天数和治疗开始后重度饮酒的关系。
Am J Psychiatry. 2020 Nov 1;177(11):1048-1059. doi: 10.1176/appi.ajp.2020.19070703. Epub 2020 Aug 28.
10
Craving and acute effects of alcohol in youths' daily lives: Associations with alcohol use disorder severity.青少年日常生活中对酒精的渴望及急性影响:与酒精使用障碍严重程度的关联。
Exp Clin Psychopharmacol. 2017 Aug;25(4):303-313. doi: 10.1037/pha0000133. Epub 2017 Jun 19.

引用本文的文献

1
Impulsive Decision Reduction Training (IDRT) reduces binge drinking and increases future orientation in young adult binge drinkers.冲动决策减少训练(IDRT)可减少年轻成年酗酒者的酗酒行为,并增强其未来导向性。
Addict Behav. 2025 Nov;170:108443. doi: 10.1016/j.addbeh.2025.108443. Epub 2025 Jul 23.
2
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?胰高血糖素样肽-1受体激动剂(GLP-1 RAs):一种治疗全脂肪性肝病的方法?
Biomedicines. 2025 Jun 20;13(7):1516. doi: 10.3390/biomedicines13071516.
3
Investigating Therapeutic Targets for Alcohol Use Disorder: Pharmacological View of ClinicalTrials.gov Data.探索酒精使用障碍的治疗靶点:基于ClinicalTrials.gov数据的药理学视角
Int J Gen Med. 2025 Jul 4;18:3701-3712. doi: 10.2147/IJGM.S530721. eCollection 2025.
4
Alcohol Use Disorder Pharmacotherapy in Patients With Alcohol-Related Liver Disease: A Scoping Review.酒精相关肝病患者的酒精使用障碍药物治疗:一项范围综述
Can J Gastroenterol Hepatol. 2025 Apr 3;2025:6455092. doi: 10.1155/cjgh/6455092. eCollection 2025.
5
Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.胰高血糖素样肽-1受体激动剂的使用与酒精摄入量变化之间的关联:一项系统综述。
EClinicalMedicine. 2024 Nov 14;78:102920. doi: 10.1016/j.eclinm.2024.102920. eCollection 2024 Dec.
6
Alcohol Consumption and Cardiovascular Disease: A Narrative Review of Evolving Perspectives and Long-Term Implications.饮酒与心血管疾病:对不断演变的观点及长期影响的叙述性综述
Life (Basel). 2024 Sep 9;14(9):1134. doi: 10.3390/life14091134.
7
Alcohol Dependence Among Adult Males in Chengalpattu District, South India: A Mixed Methods Study.印度南部金奈区成年男性中的酒精依赖:一项混合方法研究。
Cureus. 2024 Aug 11;16(8):e66624. doi: 10.7759/cureus.66624. eCollection 2024 Aug.
8
The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder.大脑内源性 D2R 多巴胺和 μ 阿片受体在酒精使用障碍中的作用。
Curr Med Chem. 2024;31(39):6393-6406. doi: 10.2174/0109298673248999231013043249.
9
Study of Cutaneous Manifestations in Alcohol Dependence Syndrome Patients in a Rural Tertiary Care Center in India.印度一家农村三级医疗中心酒精依赖综合征患者皮肤表现的研究。
Addict Health. 2023 Jan;15(1):45-52. doi: 10.34172/ahj.2023.1340. Epub 2023 Jan 29.
10
Prevalence and Treatment for Alcohol Use Disorders Based on Kentucky Medicaid 2012-2019 Datasets.基于肯塔基州医疗补助计划2012 - 2019年数据集的酒精使用障碍患病率及治疗情况
J Alcohol Drug Depend. 2022;10(5). Epub 2022 Sep 22.

本文引用的文献

1
Summary health statistics for u.s. Adults: national health interview survey, 2011.美国成年人健康统计摘要:2011年国民健康访谈调查
Vital Health Stat 10. 2012 Dec(256):1-218.
2
Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial.通过多中心随机对照试验评估双硫仑治疗酒精依赖的疗效。
Alcohol Clin Exp Res. 2014 Feb;38(2):572-8. doi: 10.1111/acer.12278. Epub 2013 Oct 11.
3
Characterizing gender differences in treatment seekers.描述治疗寻求者中的性别差异。
Alcohol Clin Exp Res. 2014 Jan;38(1):275-84. doi: 10.1111/acer.12228. Epub 2013 Aug 9.
4
Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.使用 5-HT(3) 拮抗剂昂丹司琼确定可预测酒精依赖治疗结果的基因型组合。
Am J Psychiatry. 2013 Sep;170(9):1020-31. doi: 10.1176/appi.ajp.2013.12091163.
5
S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.S-(N,N-二乙基氨基甲酰基)谷胱甘肽(氨基甲酰谷胱甘肽),一种双硫仑代谢产物及其对伏隔核和前额叶皮质多巴胺、γ-氨基丁酸和谷氨酸的影响:一项微透析研究。
Neuropharmacology. 2013 Dec;75:95-105. doi: 10.1016/j.neuropharm.2013.07.007. Epub 2013 Jul 26.
6
The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.临床试验中酒精依赖的安慰剂效应:51 项纳曲酮和安非他酮研究的探索性分析。
Alcohol Clin Exp Res. 2013 Dec;37(12):2128-37. doi: 10.1111/acer.12197. Epub 2013 Jul 24.
7
Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials.纳曲酮(50 毫克)联合心理治疗用于酒精依赖患者:一项随机对照试验的荟萃分析。
Am J Drug Alcohol Abuse. 2013 May;39(3):144-60. doi: 10.3109/00952990.2013.796961.
8
Safety and efficacy of acamprosate for the treatment of alcohol dependence.阿坎酸治疗酒精依赖的安全性和有效性。
Subst Abuse. 2013;6:1-12. doi: 10.4137/SART.S9345. Epub 2013 Jan 31.
9
The effects of drinking goal on treatment outcome for alcoholism.饮酒目标对酗酒治疗效果的影响。
J Consult Clin Psychol. 2013 Feb;81(1):13-22. doi: 10.1037/a0030886. Epub 2012 Dec 10.
10
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.在德国进行的一项针对酒精中毒的双盲、安慰剂对照药物治疗试验的结果,并与美国 COMBINE 研究进行了比较。
Addict Biol. 2013 Nov;18(6):937-46. doi: 10.1111/adb.12012. Epub 2012 Dec 12.